S 1416 · 116th Congress 2019–2021, ended

Affordable Prescriptions for Patients Act of 2019

Latest action · Jun 28, 2019 Placed on Senate Legislative Calendar under General Orders. Calendar No. 132.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedMay 9, 2019
  2. Passed SenateNot reached
  3. Passed HouseNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Affordable Prescriptions for Patients Act of 2019

This bill prohibits product hopping by drug manufacturers. Product hopping is presumed when a drug manufacturer engages is a hard switch or a soft switch. A hard switch occurs when, after a manufacturer receives notice of an application for a generic drugs, either, (1) the manufacturer obtains removal of a drug from the Food and Drug Administration’s approved drug list or the drug is moved to the discontinued products list, and the manufacturer markets or sells a follow-on product; or (2) a manufacturer announces the withdrawal or discontinuance of a listed drug, or the manufacturer destroys the inventory of a listed drug in a manner that impedes generic drug competitors, and the manufacturer markets or sells a follow-on product. A follow-on product is a changed, modified, or reformulated version of a manufacturer’s already-approved drug or biological product that still treats the same medical condition.

A soft switch occurs when a manufacturer receives notice of an application for a generic drugs, takes other actions that impede generic drug competitors, and the manufacturer markets or sells a follow-on product.

A drug manufacturer may rebut a presumption of product hopping by demonstrating that its conduct was not intended to limit competition.

This bill also limits the number of patents that may be included in infringement claims brought by approved biological product license holders against applicants for a biosimilar product license.

Cosponsors 13

Members who signed on, in the order they did. Signatures ran from May 9, 2019 to Nov 21, 2019; 1 is an original cosponsor, there from the day it was introduced.

SeatCosponsorSigned on
D-CTRichard BlumenthalOriginalMay 9, 2019
R-WVShelley Moore CapitoMay 15, 2019
D-WAPatty MurrayMay 22, 2019
R-LAJohn KennedyJun 3, 2019
R-FLRick ScottJun 3, 2019
R-MOJosh HawleyJun 4, 2019
D-ILRichard J. DurbinJun 26, 2019
I-MEAngus S. King Jr.Jul 24, 2019
D-MNTina SmithSep 12, 2019
D-MIGary C. PetersSep 25, 2019
R-NEDeb FischerNov 13, 2019
R-AZMartha McSallyNov 13, 2019
R-PAPatrick J. ToomeyNov 21, 2019

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
SenateJudiciary Committee
Referred May 9, 2019Markup Jun 27, 2019Reported Jun 28, 2019

Actions 5

Everything that happened, newest first.

  1. Jun 28, 2019Committee on the Judiciary. Reported by Senator Graham with an amendment in the nature of a substitute. Without written report.
  2. Jun 28, 2019Placed on Senate Legislative Calendar under General Orders. Calendar No. 132.
  3. Jun 27, 2019Committee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.
  4. May 9, 2019Introduced in Senate
  5. May 9, 2019Read twice and referred to the Committee on the Judiciary.

In the Congressional Record 18

Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.

WhereIn the RecordMembersDate
SenateDebate and remarks S7127John Cornyn R-TXDec 1, 2020
SenateDebate and remarks S1099John Cornyn R-TXFeb 24, 2020
SenateDebate and remarks S71John Cornyn R-TXJan 8, 2020
SenateDebate and remarks S6967, S6968Charles E. Schumer D-NY, John Cornyn R-TXDec 11, 2019
SenateDebate and remarks S6742John Cornyn R-TXNov 21, 2019

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Congressional Budget Office cost estimate

  1. Jul 19, 2019S. 1416, Affordable Prescriptions for Patients Act of 2019As reported by the Senate Committee on the Judiciary on June 28, 2019

CRS reports 2

Congressional Research Service work that CRS links to this bill or the law it became, newest first.

Cite it 2

Products on other subjects that cite it, usually among other measures.

Related bills 3

Companion bills and other measures the record links to this one.

Titles 3

Every title it has carried, official and short, at each stage.

Official Title as Introduced
A bill to amend the Federal Trade Commission Act to prohibit anticompetitive behaviors by drug product manufacturers, and for other purposes.
Short Title(s) as Introduced
Affordable Prescriptions for Patients Act of 2019
Short Title(s) as Reported to Senate
Affordable Prescriptions for Patients Act of 2019

Subjects

Assigned by the Library of Congress. Policy area: Commerce.

Text 2

Each version as it was printed, newest first.

  1. Jun 28, 2019Reported to Senate
  2. May 9, 2019Introduced in Senate

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details.

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.